{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}],"units":"Participants"}],"groups":[{"description":"Radiation Therapy on weeks 1, 3, 5, and 7 1.5 Gy/fx, twice daily x 5 days, 40 fractions, for a total dose of 60 Gy; Chemotherapy (cisplatin/paclitaxel) on weeks 1, 3, 5, and 7 G-CSF on weeks 2, 4, 6, and 8. \\[Data is reported for eligible patients with on-study information, which is 6 patients.\\]","id":"BG000","title":"Re-irradiation Plus Concurrent Chemotherapy"},{"description":"Select from one of the three standard chemotherapy regimens:\n\ncisplatin/5-FU; cisplatin/paclitaxel; cisplatin/docetaxel. \\[Data is reported for eligible patients with on-study information, which is 7 patients.\\]","id":"BG001","title":"Chemotherapy Alone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"44","upperLimit":"80","value":"56"},{"groupId":"BG001","lowerLimit":"48","upperLimit":"68","value":"57"},{"groupId":"BG002","lowerLimit":"44","upperLimit":"80","value":"57"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}